NH Therapeutics receives orphan drug designation for congenital hypogonadotropic hypogonadism

Release Date: 20-Feb-2017

NH Therapeutics, a biopharmaceutical company that focuses on developing drugs and therapies for effective treatment of rare neuroendocrine disorders, recently announced that European Medicine Agency has awarded its leading drug candidate NH-901 with orphan drug designation for the treatment of congenital hypogonadotropic hypogonadism. NH901 is a reformulation of a GnRH analogue, which has been repurposed to increase gonadotropins, sex hormones and boost fertility. The Stichting Centre for Human Drug Research (CHDR) in the Netherlands acted as the European-based sponsor on NHT's behalf.


The European Commission or European Medicine Agency grants orphan drug designation status to provide incentives to develop medicinal products to treat prevent or diagnose diseases or conditions that affect no more than five in 10,000 persons in the European Union. The orphan drug designation provides Abeona with incentives and benefits in the EU, including protocol assistance, reduced fees and protection from market competition once ABO-101 is approved for the treatment of MPS IIIB patients.


For Orphan Drug Clinical Insight Reports Contact:  neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.